Myostatin (GDF-8)
GDF-8, MSTN, growth differentiation factor 8, growth/differentiation factor 8
Myostatin is the body's principal brake on skeletal muscle growth, a protein made by muscle that tells muscle to stop growing. Animals and people who lack it are strikingly muscular, which made it one of the most attractive drug targets in modern medicine. Two decades and a dozen drug programmes later, blocking it reliably adds lean mass in humans but has repeatedly failed to make people stronger or more functional, with one recent exception.
Mechanism
Myostatin is a TGF-beta superfamily ligand secreted almost exclusively by skeletal muscle, where it acts as an autocrine and paracrine negative regulator of its own tissue. It is synthesised as a precursor, cleaved by furin-type convertases into a propeptide and a mature dimer, and released as a latent complex in which the propeptide, the latency-associated peptide, remains non-covalently bound and keeps the ligand inactive. BMP-1/tolloid metalloproteinases cleave the propeptide to liberate active myostatin. Additional extracellular regulators include follistatin, follistatin-like 3 (FSTL3), GASP-1 and GASP-2, and decorin. This is a heavily buffered system, which is a clue that its output is tightly controlled for a reason.
Active myostatin binds the activin type II receptors ActRIIB and, with lower affinity, ActRIIA. The occupied type II receptor recruits and transphosphorylates a type I receptor, ALK4 or ALK5, which phosphorylates SMAD2 and SMAD3. Phosphorylated SMAD2/3 partner with SMAD4 and translocate to the nucleus, where they suppress the myogenic transcription programme, including MyoD, myogenin and Pax7-driven satellite cell activity. In parallel, SMAD3 signalling antagonises AKT, relieving inhibition of FoxO transcription factors and permitting transcription of the muscle-specific E3 ubiquitin ligases MuRF1 and atrogin-1/MAFbx, which drive proteasomal degradation of contractile protein. The net effect is reduced protein synthesis and increased protein breakdown.
The critical complication for drug development is that ActRIIB is not myostatin's private receptor. Activin A, activin B, GDF-11 and several BMPs also signal through it. Lee's 2005 work showed that soluble ActRIIB produces far greater muscle growth than myostatin deletion alone and remains partially active in myostatin-null mice, proving that multiple ligands share the pathway. This is why the field splits into two strategies with different risk profiles: broad receptor-level blockade (soluble ActRIIB decoys such as ACE-031, anti-ActRII antibodies such as bimagrumab), which is more powerful but also blocks activin signalling in vasculature, bone marrow and reproductive tissue; and selective ligand-level blockade (antibodies against myostatin or its latent form, such as apitegromab), which is cleaner but weaker.
What the research shows
The target biology is about as solid as biology gets. McPherron, Lawler and Lee identified myostatin in 1997 and showed that knockout mice have two to three times normal muscle mass, from both hyperplasia and hypertrophy. Naturally occurring loss-of-function mutations explain the double-muscled Belgian Blue and Piedmontese cattle, the muscular Whippet phenotype and hypertrophic sheep. In 2004 Schuelke and colleagues reported a child with a loss-of-function splice-site mutation in MSTN presenting with marked muscle bulk and unusual strength, the human proof of principle, published in the New England Journal of Medicine. Nothing in the subsequent two decades has undermined this.
Translation is where it falls apart, and the pattern is remarkably consistent. MYO-029 (stamulumab), an anti-myostatin antibody, was the first into patients; Wagner's 2008 randomised placebo-controlled trial in adult muscular dystrophies found it safe but showed no significant improvement in strength or function. Domagrozumab failed to meet its primary endpoint in Duchenne muscular dystrophy. Landogrozumab and trevogrumab produced lean-mass gains without convincing functional benefit. Bimagrumab, a bivalent anti-ActRII antibody and the most potent agent tested, reliably increases lean mass and reduces fat mass: Heymsfield and colleagues reported significant body fat mass reduction in adults with type 2 diabetes and obesity in a Phase 2 randomised trial (JAMA Network Open 2021;4(1):e2033457). But Rooks and colleagues found in a randomised sarcopenia trial that the added lean mass did not produce the expected gait-speed benefit over optimised standard care, and bimagrumab previously failed its primary endpoint in sporadic inclusion body myositis. The recurring lesson is that myostatin blockade builds tissue mass that is not fully functional muscle; preclinical work by Relizani and colleagues found that ActRIIB blockade can induce fatigability and a metabolic myopathy.
The exception, and it is an important one, is apitegromab. This antibody binds the pro- and latent forms of myostatin rather than the mature ligand, and it was tested in spinal muscular atrophy on a background of SMN-targeted therapy, a setting where the muscle is denervated then reinnervated and the limiting factor may genuinely be muscle mass. The Phase 3 SAPPHIRE trial enrolled 188 patients in total: a main efficacy population of 156 non-ambulatory patients with type 2 or type 3 SMA aged 2-12, randomised 1:1:1 to apitegromab 10 mg/kg, 20 mg/kg or placebo intravenously every four weeks for 12 months, plus an exploratory cohort of 32 aged 13-21. In the 2-12 population the pooled apitegromab groups showed a least-squares mean difference of 1.8 points on the Hammersmith Functional Motor Scale Expanded versus placebo (95% CI 0.30 to 3.32, p = 0.019), published in Lancet Neurology in 2025. That is a modest but real functional win, and the first for this drug class.
More broadly, the ActRII pathway has produced one approved medicine, though not for muscle: sotatercept, an ActRIIA-Fc fusion, was approved by FDA in March 2024 for pulmonary arterial hypertension. Bimagrumab has since been repurposed as a lean-mass-preserving partner for incretin weight-loss drugs, with Phase 2b results reported in 2025 indicating that combination with semaglutide produced substantial weight loss with the great majority of the lost mass coming from fat rather than lean tissue. Those combination results were reported through company and conference channels; the precise figures circulating should be treated as provisional until the full peer-reviewed publication is available.
Evidence assessment
Mixed evidence
Myostatin's role as a negative regulator of human muscle mass is established beyond dispute by human genetics, but the clinical results of blocking it are genuinely conflicting: multiple randomised trials show consistent lean-mass gains alongside repeated failures on functional endpoints, with apitegromab in spinal muscular atrophy the first clear functional success.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member Preclinical only
Myostatin-null mice showed two to three times normal skeletal muscle mass from both hyperplasia and hypertrophy, identifying myostatin as a negative regulator of muscle growth.
Myostatin mutation associated with gross muscle hypertrophy in a child Limited evidence
A child with a loss-of-function MSTN splice-site mutation showed marked muscle hypertrophy and unusual strength, establishing the human relevance of the target.
Regulation of muscle growth by multiple ligands signaling through activin type II receptors Preclinical only
Soluble ActRIIB produced large increases in muscle mass within two weeks in wild-type mice and remained active, though attenuated, in myostatin-null mice, showing that ligands beyond myostatin regulate muscle through this receptor.
A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy Mixed evidence
The anti-myostatin antibody was well tolerated but produced no significant improvement in muscle strength or function, the first clinical failure of the class.
Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial Mixed evidence
Bimagrumab increased lean mass and reduced fat mass but did not produce additional benefit in gait speed over optimised standard care alone.
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial Mixed evidence
Bimagrumab reduced body fat mass and increased lean mass relative to placebo over the treatment period.
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial High-quality evidence
In the 2-12 population the pooled apitegromab groups showed a least-squares mean difference of 1.8 points on the Hammersmith Functional Motor Scale Expanded versus placebo (95% CI 0.30 to 3.32, p = 0.019), the first clear functional benefit for a myostatin-directed agent in a phase 3 trial.
Safety
Myostatin itself is endogenous and is not administered. The safety questions concern blocking it, and they differ sharply by strategy.
Broad ActRII blockade has produced the clearest signals. ACE-031, a soluble ActRIIB decoy, was halted in Duchenne muscular dystrophy over epistaxis and telangiectasias, small-vessel effects that reflect the role of activin and BMP signalling in vascular endothelium. Sotatercept, an ActRIIA-Fc fusion approved for pulmonary arterial hypertension, carries labelled warnings for erythrocytosis, severe thrombocytopenia and serious bleeding events, and epistaxis is among its common adverse reactions. Bimagrumab's characteristic adverse effects are muscle spasms, diarrhoea and acne, generally mild, but its long-term profile in the large populations now being considered for incretin combination therapy is not established.
Selective anti-myostatin antibodies have been comparatively well tolerated. MYO-029 was safe at the doses tested. Apitegromab's Phase 3 safety profile was broadly comparable to placebo, with pyrexia reported in 26% of apitegromab recipients versus 28% on placebo. This tolerability advantage is the flip side of its weaker effect.
There are two conceptual cautions worth stating. First, muscle gained through myostatin blockade is not necessarily normal muscle: preclinical work by Relizani and colleagues found that ActRIIB blockade triggered fatigability and a metabolic myopathy, with hypertrophied fibres showing impaired oxidative capacity. Mass and function are not the same variable, which is the most parsimonious explanation for the field's repeated functional failures. Second, myostatin and activin signalling are involved in tissue homeostasis well beyond muscle, including bone, adipose tissue, vasculature, reproductive endocrinology and, in several tissues, tumour suppression. Chronic systemic blockade in otherwise healthy people, as opposed to time-limited use in a defined disease, has never been studied and should not be assumed benign.
For completeness: there is no myostatin product that anyone would rationally inject, and 'myostatin' sold as a research peptide would be the growth-inhibitory ligand itself, not an inhibitor of it.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA-authorised myostatin-targeting medicine for muscle disease. A European marketing authorisation application for apitegromab has been filed, with a UK route to follow; regulatory status was not independently verified during this audit and should be checked against the current MHRA and EMA registers. Sotatercept holds a marketing authorisation for pulmonary arterial hypertension. Any myostatin inhibitor supplied outside these routes for human use would be an unlicensed medicinal product under the Human Medicines Regulations 2012. Not controlled under the Misuse of Drugs Act 1971. |
| United States | No myostatin-targeting drug is currently FDA-approved for a muscle indication. Apitegromab's biologics licence application received a Complete Response Letter in 2025 that related to third-party fill-finish manufacturing observations rather than to efficacy or safety, and was resubmitted; the specific action date could not be independently confirmed during this audit and is not stated here. MYO-029, domagrozumab, landogrozumab and ACE-031 were all discontinued. Bimagrumab is investigational, in development for lean-mass preservation alongside incretin therapy. Sotatercept (an ActRIIA-Fc fusion) was approved in March 2024 for pulmonary arterial hypertension, the only approved medicine acting on this receptor family. Myostatin itself is an endogenous protein and is not a regulated drug substance. |
| WADA (sport) | Agents that block this pathway are prohibited at all times. The WADA Prohibited List, section S4.3 (Agents preventing activin receptor IIB activation), prohibits activin A-neutralising antibodies, decoy activin receptors (naming ACE-031), anti-activin receptor IIB antibodies (naming bimagrumab), agents reducing or ablating myostatin expression, myostatin-binding proteins (naming follistatin and myostatin propeptide) and myostatin- or precursor-neutralising antibodies (naming apitegromab, domagrozumab, landogrozumab and stamulumab). Substances in S4.3 are Specified Substances. A combined LC-HRMS/MS screening method for this class was published in 2025 (Sakellariou et al.). |
Questions
It is skeletal muscle's own brake. Muscle secretes myostatin, which binds activin type II receptors and signals through SMAD2/3 to suppress the myogenic transcription programme, block satellite cell activation and permit the muscle-wasting ubiquitin ligases MuRF1 and atrogin-1. Animals and humans lacking functional myostatin have markedly more muscle, which is why it became one of the most pursued drug targets in the field.
Because mass and function turn out to be different things. Drugs including MYO-029, domagrozumab, landogrozumab and bimagrumab reliably added lean mass in randomised trials, but repeatedly failed to improve strength, walking or gait speed. Preclinical work suggests hypertrophied fibres produced by blocking this pathway can have impaired oxidative capacity and increased fatigability. Apitegromab in spinal muscular atrophy is the first phase 3 success, and it worked in a setting where muscle mass was plausibly the limiting factor.
Not legitimately. Every myostatin-directed agent with real evidence behind it is a monoclonal antibody or a receptor-Fc fusion protein produced in mammalian cell culture: large, glycosylated biologics that cannot be synthesised as peptides and are not available outside clinical trials or, in sotatercept's case, prescription. Products sold online as myostatin inhibitors are not those molecules. All agents in this class are prohibited in sport at all times under WADA section S4.3.
Yes. GDF-8 (growth differentiation factor 8) is the systematic name and myostatin the common one, for the protein encoded by the human MSTN gene. It is closely related to GDF-11, which shares the same receptors and much of the same signalling machinery; that overlap is one reason broad receptor-level blockade produces effects beyond muscle.